Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the ‘Company’ or ‘Bold’) is pleased to highlight news from the area of its Burchell Gold and Copper Property (‘Burchell’ or the ‘Property’), while anticipating channel sampling results from its recent mechanical stripping program at Burchell. Nearly 300 channel samples are currently being analyzed, with sampling ongoing.

Gold X2 Mining Inc. (‘Gold X2’), which holds the Moss Project adjoining Burchell to the west, recently announced a definitive agreement to acquire Kesselrun Resources Ltd. (GoldX2 October 1, 2025 news release), their neighbour to the west where they have recently been exploring the Huronian Gold Project. The acquisition reflects Gold X2’s strategy of consolidating their land position in the western portion of the Shebandowan Greenstone Belt. See Map of Land Positions and Major Showings for locations of these land positions relative to the Burchell Property.

Bold Management shares the belief in the district’s significant potential for new discoveries. During the past summer, Bold identified a 2.9 km trend of gold mineralization in rock sampling (Bold September 11, 2025 news release). Following this, the exploration team has recently exposed and sampled bedrock in 8 different locations along a 900-meter portion of this ‘111 Gold Trend.’ All 8 stripped areas have never been explored in the past, demonstrating the untapped potential of the area and the Burchell claim group.

Gold X2 also recently announced the delineation of a 5 km trend of gold mineralization south of the Moss Trend, outlining several targets which mirror the geochemical and geophysical fingerprints of the Moss Gold Deposit (Gold X2 October 16, 2025 news release). Based on this interpretation, it appears that the anomalous in gold Deaty Trend strikes northeast towards the Burchell Gold and Copper Project boundary. The southwest end of the 111 Gold Trend is located within 800 m of the west boundary, where a new gold showing named the ‘Moosehead Zone’ was identified earlier in the summer, hosted in sheared quartz feldspar porphyry, with one grab sample returning 371 ppb Au (see Bold’s September 11, 2025 news release). Further north of the Moosehead Zone, historic trenches have reportedly yielded a chip sample of 42.2 g/t Au over 0.6 meters (Osmani 2017), approximately 600 meters from the western property boundary. The Hermia Copper Prospect is located approximately 900 m from the Burchell west boundary. See Map of Land Positions and Major Showings. While the results of the Gold X2 work adjacent to Burchell is very encouraging it does not indicate that the same conditions exist within the Burchell claims.

Bruce MacLachlan, President and COO of Bold, commented, ‘The activity by Gold X2 and our own exploration programs this year mark an exciting new era for the western Shebandowan Greenstone Belt, especially with gold prices surging to all-time highs. We are anticipating results from our channel sampling program and our next step will be to prepare for a drill program.’

The Hermia Cu Prospect – Located in the western part of the property, hosted in a zone of deformed felsic to mafic volcanics containing Cu mineralization associated with minor Au, Ag, Mo, Zn and Ni. Historical diamond drilling was carried out over a strike length of 2.8 km from 1964 to 2008. Intersections in core include 0.8% Cu over 4.3 m, 0.25% Cu over 51.9 m, and 1.68 g/t Au over 1.45 m (Ontario Assessment File Database). See Map of Hermia Copper Trend (from Osmani 2017).

A diamond drilling data compilation is currently ongoing for the Burchell Property, which will inform the next steps for exploring the Hermia Cu Prospect, which to date hosts the most significant copper mineralization on the property.

Ring of Fire Optimism:

Bold Ventures would like to draw attention to the recent CIM Northern Luncheon in North Bay, an event drawing together mining professionals, where the topic of the Ring of Fire sparked optimism for future opportunities. Bold is pleased to see support for the development of the critical mineral projects in this strategically important district.

Bold’s Koper Lake Project in the Ring of Fire:

Bold holds a 10% carried interest (through to production) in the Black Horse Chromite NI 43-101 Inferred Resource of 85.9 Mt grading 34.5% Cr₂O3 at a cut-off of 20% Cr₂O₃ (KWG Resources Inc., NI 43-101 Technical Report, Aubut 2015). Bold also holds a 40% working interest in all other metals found within the Koper Lake Project and has a Right of First Refusal on a 1% NSR covering all metals found within the claim group.

Other news:

Bold Ventures also announces the acquisition of 8 new claims adjoining its Joutel project in Québec. The new claims cover an additional VTEM^TM anomaly identified by Bold’s 2011 airborne survey. The project now comprises 49 claims covering 2714 hectares.

The technical information in this news release was reviewed and approved by Coleman Robertson, B.Sc., P. Geo., the Company’s V.P. of Exploration and a qualified person (QP) for the purposes of NI 43-101.

References:

Osmani, A., 2017. NI 43-101 Technical Report on the Burchell Lake Property, Northwestern Ontario, Thunder Bay Mining District, NTS 52B/10SE, for Tanager Energy Inc.

Bold Ventures management believes our suite of Battery, Critical and Precious Metals exploration projects are an ideal combination of exploration potential meeting future demand. Our target commodities are comprised of: Copper (Cu), Nickel (Ni), Lead (Pb), Zinc (Zn), Gold (Au), Silver (Ag), Platinum (Pt), Palladium (Pd) and Chromium (Cr). The Critical Metals list and a description of the Provincial and Federal electrification plans are posted on the Bold Critical and Battery Minerals page.

About Bold Ventures Inc.

The Company explores for Precious, Battery and Critical Metals in Canada. Bold is exploring properties located in active gold and battery metals camps in the Thunder Bay and Wawa regions of Ontario. Bold also holds significant assets located within and around the emerging multi-metals district dubbed the Ring of Fire region, located in the James Bay Lowlands of Northern Ontario.

Direct line: (705) 266-0847

Email: bruce@boldventuresinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words ‘may’, ‘would’, ‘could’, ‘will’, ‘intend’, ‘plan’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’ and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION
IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271043

(TheNewswire)

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia TheNewswire – October 20th, 2025 Prismo Metals Inc. (the ‘ Company ‘) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce a non-brokered private placement (the ‘ Private Placement ‘) of 12.5 million units of the Company (‘ Units ‘) at an issue price of $0.10 per Unit for minimum gross proceeds of $1,250,000. Each Unit will consist of one common share in the capital of the Company (a ‘ Share ‘) and one-half of one common share purchase warrant of the Company (each whole warrant, a ‘ Warrant ‘). Each Warrant will entitle the holder to purchase one Share for a period of thirty-six (36) months from the date of issue at an exercise price of $0.175. The Warrants will contain an accelerated expiry clause (the ‘ Acceleration Clause ‘). Pursuant to the Acceleration Clause, if the Shares of the Company close at or above $0.25 for ten (10) consecutive trading days on the Canadian Securities Exchange (‘ CSE ‘), then the Company may accelerate the expiry date of the Warrants by issuing a news release announcing the accelerated Warrant term, pursuant to which the Warrants will expire on the 30th calendar days after the date of such news release.

The Company intends to use the net proceeds of the Private Placement primarily for drilling at its Silver King project and for general corporate purposes . In August 2025, Prismo submitted a plan of operations for the drill program with the Forest Service in Arizona. The first phase of drilling at Silver King will consist of a minimum of 1,000 meters.

Dr. Craig Gibson, Chief Exploration Officer of Prismo commented: ‘This first phase is designed to test the upper half of the steeply dipping pipelike Silver King mineralized body as well as potentially mineralization adjacent to the dense stockwork that was the focus of historic mining. Follow up drilling will expand on the initial program based on the results and may include separate targets outside of the historic mining area, such as the polymetallic vein mentioned above. The discovery of the two mineralized veins and porphyry style mineralization has resulted in Prismo evaluating a larger drill program to test those targets.’

Dr. Gibson added: ‘We have also received the overlimit assays for silver for four samples from the Ripsey mine, which range from 132 to 224 g/t Ag. These results confirm the high-grade nature of the mineralization along the Ripsey vein, exposed at the surface and in underground workings over about 600 meters along strike.’

Click Image To View Full Size

Figure 1. Proposed drill pads for the Silver King project in the process of being permitted.

Figure 2 . Cross section through the Silver King mine workings showing proposed drill holes (in black) to test the pipelike mineralized body (in red)

The Private Placement will also be made available to existing shareholders of the Company who, as of the close of business on October 18th, 2025, held Shares (and who continue to hold such Shares as of the closing date of the Private Placement), pursuant to the existing securityholder exemption set out in BC Instrument 45-534 – Exemption From Prospectus Requirement for Certain Trades to Existing Security Holders (the ‘ Existing Securityholder Exemption ‘). The Existing Securityholder Exemption limits a shareholder to a maximum investment of CAD$15,000 in a 12-month period unless the shareholder has obtained advice regarding the suitability of the investment and, if the shareholder is resident in a jurisdiction of Canada, that advice has been obtained from a person that is registered as an investment dealer in the jurisdiction. If the Company receives subscriptions from investors relying on the Existing Securityholder Exemption exceeding the maximum amount of the Private Placement, the Company intends to adjust the subscriptions received on a pro-rata basis.

The Units issued pursuant to the Private Placement, and the Existing Securityholder Exemption will be subject to a four-month hold period from the closing date of the Private Placement under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

The Company may pay finder’s fees to eligible finders in connection with the Private Placement, subject to compliance with applicable securities laws and Canadian Securities Exchange policies.

The securities being offered have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons or persons in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Ripsey Gold Project Overlimit Assay Results

The Company has also received the overlimit assays for silver for four samples from the Ripsey mine, ranging from 132 to 224 g/t Ag, announced October 16, 2025 (Table 1).  These results confirm the high-grade nature of the mineralization along the Ripsey vein, exposed at the surface and in underground workings over about 600 meters along strike.

Table 1. Assay results for samples taken of the Ripsey vein

Qualified Person

Dr. Craig Gibson, PhD., CPG., a Qualified Person as defined by NI-43-01 regulations and Chief Exploration Officer and a director of the Company, has reviewed and approved the technical disclosures in this news release. Other than the sampling conducted by Dr. Craig Gibson as indicated herein, the data presented in this press release was obtained from public sources, should be considered incomplete and is not qualified under NI 43-101, but is believed to be accurate. The Company has not verified the historical data presented and it cannot be relied upon, and it is being used solely to aid in exploration plans.

About the Silver King

Discovered in 1875, the Silver King mine was one of Arizona ‘ s most important historic producers, yielding nearly 6 million ounces of silver at grades of up to 61 oz/t.  The Silver King mine sits only 3 km from the main shaft of the Resolution Copper project — a joint venture between Rio Tinto and BHP and one of the world ‘ s largest unmined copper deposits with an estimated copper resource of 1.787 billion metric tonnes at an average grade of 1.5% copper (1) . The unique land position is fully surrounded by Resolution Copper ‘ s claim block, offering strategic upside. Selected samples from small-scale production in the late 1990s returned grades as high as 644 oz/t silver (18,250 g/t) and 0.53 oz/t gold (15 g/t), indicating that high-grade mineralization remains.

About Prismo Metals Inc.

Prismo (CSE: PRIZ,OTC:PMOMF) is a mining exploration company focused on advancing its Silver King, Ripsey and Hot Breccia projects in Arizona and its Palos Verdes silver project in Mexico.

Please follow @PrismoMetals on , , , Instagram , and

Prismo Metals Inc.

1100 – 1111 Melville St., Vancouver, British Columbia V6E 3V6

Phone: (416) 361-0737

Contact:

Alain Lambert, Chief Executive Officer alain.lambert@prismometals.com

Gordon Aldcorn, President gordon.aldcorn@prismometals.com

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’ or ‘anticipates’, or  variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. This information and these statements, referred to herein as ‘forward‐looking statements’, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: the timing, costs and results of drilling at Silver King.

These forward‐looking statements involve numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: delays in obtaining or failure to obtain appropriate funding to finance the exploration program at Silver King.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the ability to raise capital to fund the drilling campaign at Silver King and the timing of such drilling campaign.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Copyright (c) 2025 TheNewswire – All rights reserved.

Manhattan Showing with assay results returning uranium grades ranging from 0.72% to 8.10% U3O8 in outcrop grab samples.

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) (‘Standard Uranium’ or the ‘Company’) is pleased to announce final assay results from its 2025 exploration programs the Corvo Uranium Project (‘Corvo’, or the ‘Project’), currently under a three-year earn-in option agreement with Aventis Energy Inc. (‘Aventis’) (CSE: AVE).

From July 4 to July 16, 2025, the Company completed a detailed mapping and sampling program across historical uranium showings and zones of interest on the Project. Assay results confirm uranium mineralization across the Project, including high-grade^* surface mineralization at the Manhattan Showing.

Highlights:

• High-Grade Uranium at Surface: Verification of surficial uranium mineralization across the Project, including the historical Manhattan Showing with assay results returning uranium grades ranging from 0.72% to 8.10% U₃O₈ in outcrop grab samples.

• Discovery of New Radioactive Showings: Scintillometer prospecting uncovered previously undocumented radioactive occurrences across the Project in favorable rock types for uranium and Rare Earth Element (‘REE’) mineralization.

• Ongoing Exploration: An extensive ground gravity survey is scheduled for December 2025, designed to identify density anomalies potentially representing hydrothermal alteration systems coincident with newly refined EM conductor trends across the Project. A diamond drill program is being planned for Q1 2026 to begin testing targets developed and ranked through the successful programs executed in 2025.

‘Our geochemical assays returning the highest uranium grades ever reported on the Project increases our confidence and excitement, as we were able to repeat historic results and identify new areas of mineralization at surface,’ said Sean Hillacre, President & VP Exploration of Standard Uranium. ‘We will continue to bolster our targeting strategy through the December ground gravity program leading into the first drill program on the Project in more than 40 years.’

Figure 1. Regional map of the Corvo Project. The Project is located 60 km due east of Cameco’s McArthur River mine and 45 km northeast of Atha Energy’s Gemini Mineralized Zone (‘GMZ’).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10633/270985_03afcce444773bc1_001full.jpg

2025 Prospecting Program – Geochemical Assay Results

Beginning July 4 and concluding July 16, 2025, the Standard Uranium technical team completed a detailed mapping, prospecting, and sampling program to ground-truth historical uranium showings at surface on the Project. Prospecting confirmed several uraniferous outcrops and boulders across the Project, including at the Manhattan showing (0.72% to 8.10% U₃O₈; Figure 2).

A total of 30 outcrop and boulder grab samples were submitted to Saskatchewan Research Council Geoanalytical Laboratories in Saskatoon, SK, an ISO/IEC 17025:2017 and Standards Council of Canada certified analytical laboratory, for whole-rock, uranium, and REE geochemical analysis. Uranium and Total Rare Earth Element Oxides including Yttrium oxide (TREO*) results from 28 radioactive samples are summarized below in Table 1. Oxide TREO* values in Table 1 refer to total amounts of the REE oxides in the lanthanide series plus the chemically similar element Yttrium (Y₂O₃). Parts per million (‘ppm’) values are converted to oxide wt.% values through the applicable conversion factor relating to each REE oxide and then summed³.

Table 1. Corvo 2025 Prospecting Uranium and TREO* Geochemical Assays

Figure 2. Manhattan Showing high-grade samples (Left) Hand sample 244959 – 5.14 wt.% U₃O₈ (Right) Hand sample 214010 – 8.10 wt.% U₃O₈. Scale bars units are metric (cm / mm).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10633/270985_03afcce444773bc1_002full.jpg

Corvo Exploration

Supplementary geophysical surveys across the Project have been designed to further refine drill targets for an inaugural drill program in 2026. The Company will complete a high-resolution ground gravity survey across the main conductive trends on the Project, aiming to identify potential hydrothermal alteration halos which could be related to basement-hosted uranium mineralization.

Earlier this year, the Company contracted Axiom Exploration Group Ltd. in partnership with New Resolution Geophysics to carry out a helicopter-borne Xcite time domain electromagnetic and total field magnetic survey over the Corvo Project². The survey totalled approximately 1,380 line-kms with a traverse line spacing of 100 m and tie-line spacing of 1,000 m. The airborne TDEM survey outlines several kilometers of conductive anomalies and magnetic features in bedrock, effectively enhancing the resolution of more than 29 kilometres of conductive trends on the project.

Ongoing geophysical interpretation and modeling is being completed to integrate historical surveys with newly collected datasets, which will provide high-priority drill targets and significantly derisk the Project prior to modern drilling in 2026.

The Company believes the Project is highly prospective for the discovery of shallow, high-grade basement-hosted uranium mineralization akin to the Rabbit Lake deposit and the recently discovered Gemini Mineralized Zone. Located just outside the current margin of the Athabasca Basin, Corvo boasts shallow drill targets with bedrock under minimal cover of glacial till.

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed, verified, and approved by Sean Hillacre, P.Geo., President and VP Exploration of the Company and a ‘qualified person’ as defined in NI 43-101 – Standards of Disclosure for Mineral Projects.

Samples collected for analysis were sent to SRC Geoanalytical Laboratories in Saskatoon, Saskatchewan for preparation, processing, and ICP-MS or ICP-OES multi-element analysis using total and partial digestion and boron by fusion. Radioactive samples were tested using the ICP1 uranium multi-element exploration package plus boron. All samples marked as radioactive upon arrival to the lab were also analyzed using the U₃O₈ assay (reported in wt.%). SRC is an ISO/IEC 17025:2005 and Standards Council of Canada certified analytical laboratory. Blanks, standard reference materials, and repeats were inserted into the sample stream at regular intervals in accordance with Standard Uranium’s quality assurance/quality control (QA/QC) protocols. All samples passed internal QA/QC protocols and the results presented in this release are deemed complete, reliable, and repeatable.

REE oxide conversion factors³ were verified using the following formulas:
Convert REE (Rare Earth Element) ppm to REO (Rare Earth Oxide): REO % = (ppm / Atomic Weight of REE) * (Molecular Weight of REO / 10,000).

Element-to-oxide conversion factor: Molecular weight of the oxide / atomic weight of the element. For oxides with more than one metal cation, account for the number of cations in the formula.

Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company’s future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization.

Natural gamma radiation from rocks reported in this news release was measured in counts per second (‘cps’) using a handheld RS-125 super-spectrometer and RS-120 super-scintillometer. Readers are cautioned that scintillometer readings are not uniformly or directly related to uranium grades of the rock sample measured and should be treated only as a preliminary indication of the presence of radioactive minerals. The RS-125 and RS-120 units supplied by Radiation Solutions Inc. (‘RSI’) have been calibrated on specially designed Test Pads by RSI. Standard Uranium maintains an internal QA/QC procedure for calibration and calculation of drift in radioactivity readings through three test pads containing known concentrations of radioactive minerals. Internal test pad radioactivity readings are known and regularly compared to readings measured by the handheld scintillometers for QA/QC purposes.

References
¹ SMDI# 2052: https://mineraldeposits.saskatchewan.ca/Home/Viewdetails/2052 & Mineral Assessment Report MAW00047: Eagle Plains Resources Inc., 2011-2012
²Standard Uranium Provides Exploration Update Highlighting Results of Gravity and TDEM Surveys on Three Eastern Athabasca Uranium Projects, News Release, March 13, 2025. https://standarduranium.ca/news-releases/standard-uranium-provides-exploration-update-tdem-surveys-on-three-eastern-athabasca-uranium/
³https://www.jcu.edu.au/advanced-analytical-centre/resources/element-to-stoichiometric-oxide-conversion-factors
^*The Company considers uranium mineralization with concentrations greater than 1.0 wt% U₃O₈ to be ‘high-grade’.
^**The Company considers radioactivity readings greater than 65,535 counts per second (cps) on a handheld RS-125 Super-Spectrometer to be ‘off-scale’.
^***The Company considers radioactivity readings greater than 300 counts per second (cps) on a handheld RS-125 Super-Spectrometer to be ‘anomalous’.

About Standard Uranium (TSXV: STND,OTC:STTDF)

We find the fuel to power a clean energy future

Standard Uranium is a uranium exploration company and emerging project generator poised for discovery in the world’s richest uranium district. The Company holds interest in over 235,435 acres (95,277 hectares) in the world-class Athabasca Basin in Saskatchewan, Canada. Since its establishment, Standard Uranium has focused on the identification, acquisition, and exploration of Athabasca-style uranium targets with a view to discovery and future development.

Standard Uranium’s Davidson River Project, in the southwest part of the Athabasca Basin, Saskatchewan, comprises ten mineral claims over 30,737 hectares. Davidson River is highly prospective for basement-hosted uranium deposits due to its location along trend from recent high-grade uranium discoveries. However, owing to the large project size with multiple targets, it remains broadly under-tested by drilling. Recent intersections of wide, structurally deformed and strongly altered shear zones provide significant confidence in the exploration model and future success is expected.

Standard Uranium’s eastern Athabasca projects comprise over 43,185 hectares of prospective land holdings. The eastern basin projects are highly prospective for unconformity related and/or basement hosted uranium deposits based on historical uranium occurrences, recently identified geophysical anomalies, and location along trend from several high-grade uranium discoveries.

Standard Uranium’s Sun Dog project, in the northwest part of the Athabasca Basin, Saskatchewan, is comprised of nine mineral claims over 19,603 hectares. The Sun Dog project is highly prospective for basement and unconformity hosted uranium deposits yet remains largely untested by sufficient drilling despite its location proximal to uranium discoveries in the area.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains ‘forward-looking statements’ or ‘forward-looking information’ (collectively, ‘forward-looking statements’) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the timing and content of upcoming work programs; geological interpretations; timing of the Company’s exploration programs; and estimates of market conditions.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements are highlighted in the ‘Risks and Uncertainties’ in the Company’s management discussion and analysis for the fiscal year ended April 30, 2025.

Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies that may cause the Company’s actual financial results, performance, or achievements to be materially different from those expressed or implied herein. Some of the material factors or assumptions used to develop forward-looking statements include, without limitation: that the transaction with the Optionee will proceed as planned; the future price of uranium; anticipated costs and the Company’s ability to raise additional capital if and when necessary; volatility in the market price of the Company’s securities; future sales of the Company’s securities; the Company’s ability to carry on exploration and development activities; the success of exploration, development and operations activities; the timing and results of drilling programs; the discovery of mineral resources on the Company’s mineral properties; the costs of operating and exploration expenditures; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); uncertainties related to title to mineral properties; assessments by taxation authorities; fluctuations in general macroeconomic conditions.

The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking statements and the assumptions made with respect thereto are made as of the date of this news release and, accordingly, are subject to change after such date. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270985

Eric Sprott announces that, on October 17, 2025, 2176423 Ontario Ltd., a corporation beneficially owned by him, acquired 4,637,960 common shares (Shares) of Silver Mining Ltd. (Silverco Mining) (being approximately 14.2% of the outstanding Shares) pursuant to the closing of the reverse takeover transaction (Transaction) of Quetzal Copper Corp. (now named ‘Silverco Mining Ltd.’) with Silverco Mining Corp. (Target). The closing of the Transaction is further described in the news release of Silverco Mining dated October 17, 2025. In connection with the Transaction shareholders of the Target received 1.88 Shares for each common share of the Target they held, with each such Share having a deemed price of $1.60.

Prior to the Transaction, Mr. Sprott did not own any Shares, but beneficially owned and controlled 2,467,000 common shares of the Target. In connection with the Transaction, Mr. Sprott acquired 4,637,960 Shares for total deemed consideration of $7,420,736.

The Shares are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities of Silverco Mining including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions, in the future depending on market conditions, reformulation of plans and/or other relevant factors.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271010

• MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.

• New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.

• Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the successful completion of a private placement offering (the ‘Offering’) of units (‘Units’) for net proceeds of US$11 million. The initial closing of US$10 million has been completed, with the remaining US$1 million to close on Monday, October 20, 2025.

‘As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct investment of US$11 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial,’ said David Elsley, President and CEO of Cardiol Therapeutics. ‘Topline results from our ARCHER trial demonstrated a significant reduction in LV mass-marking the first evidence of structural and remodeling improvement in patients with myocarditis. This landmark finding represents our second clinical validation in inflammatory heart disease and establishes a key translational link to data published earlier this year in the Journal of the American College of Cardiology, which demonstrated the beneficial effects of the active pharmaceutical ingredient or API in CardiolRx on cardiac structure, inflammation, and fibrosis in a model of heart failure. The ARCHER findings support pursuing an additional Orphan Drug Designation for CardiolRx in myocarditis and advancing the development of our next-generation CRD-38 formulation, which delivers the same API via subcutaneous administration, to target the broader heart failure market. Notably, blockbuster drugs that reduce LV mass have been shown to lower heart failure-related death and hospitalization, underscoring the clinical potential of Cardiol’s differentiated anti-inflammatory mechanism to address a large unmet need in heart failure, where five-year mortality rates still exceed 50%.’

Under the Offering, the Company sold a total of 11 million Units at a price of US$1.00 per Unit. Each Unit consists of one Class A common share of the Company (a ‘Common Share‘) and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one additional Common Share at an exercise price of US$1.35 for a period of 24 months from the date of issuance. The warrants include an acceleration provision, allowing the Company to advance their expiry to the 30^th day following the issuance of a news release if the daily volume-weighted average trading price of the Common Shares exceeds US$2.00 for five consecutive trading days. Proceeds from the Offering provide cash resources that are anticipated to support operations into the third quarter of 2027.

The securities have not been registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the ‘United States’ or ‘U.S. persons’ (as such terms are used in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Certain insiders of the Company participated in the Offering. Such participation is considered to be a ‘related-party transaction’ within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related-party participation in the Offering as the fair market value (as determined under MI 61-101) of the subject matter of, and the fair market value of the consideration for, the transaction, insofar as it involved interested parties, did not exceed 25% of the Company’s market capitalization (as determined under MI 61-101).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

The ARCHER Program (NCT05180240) comprises the completed Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, and statements regarding the expected length and scope of funding for the Company’s development plans as a result of the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270946